1. Home
  2. LXU vs OMER Comparison

LXU vs OMER Comparison

Compare LXU & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LSB Industries Inc.

LXU

LSB Industries Inc.

N/A

Current Price

$13.63

Market Cap

859.0M

Sector

Industrials

ML Signal

N/A

Logo Omeros Corporation

OMER

Omeros Corporation

N/A

Current Price

$11.26

Market Cap

821.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LXU
OMER
Founded
1968
1994
Country
United States
United States
Employees
513
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
859.0M
821.7M
IPO Year
2006
2008

Fundamental Metrics

Financial Performance
Metric
LXU
OMER
Price
$13.63
$11.26
Analyst Decision
Buy
Strong Buy
Analyst Count
4
5
Target Price
$10.94
$32.50
AVG Volume (30 Days)
788.8K
751.6K
Earning Date
05-29-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
225.93
N/A
EPS
0.34
N/A
Revenue
$615,208,000.00
$29,868,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$2.44
N/A
P/E Ratio
$39.51
N/A
Revenue Growth
17.77
N/A
52 Week Low
$4.88
$2.95
52 Week High
$14.65
$17.65

Technical Indicators

Market Signals
Indicator
LXU
OMER
Relative Strength Index (RSI) 78.19 43.42
Support Level $7.36 $11.09
Resistance Level N/A $11.90
Average True Range (ATR) 0.70 0.48
MACD 0.34 -0.01
Stochastic Oscillator 80.44 13.91

Price Performance

Historical Comparison
LXU
OMER

About LXU LSB Industries Inc.

LSB Industries Inc is engaged in the manufacturing and sale of chemical products in the United States. The company manufactures and sells chemical products for the agricultural and industrial sectors. Its products include ammonia, fertilizer grade ammonium nitrate (AN and HDAN), and urea ammonia nitrate (UAN) for agricultural applications; high purity and commercial grade ammonia, sulfuric acids, concentrated, blended, and regular nitric acid, mixed nitrating acids, carbon dioxide, and diesel exhaust fluid for industrial applications; and industrial grade AN (LDAN) and AN solutions for mining applications. Its products are sold through distributors and directly to end customers throughout the United States and other parts of North America.

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Share on Social Networks: